Thursday, April 18, 2024 11:27:14 PM
Mentioned: NKGN
GlobeNewswireApril 18, 2024
SANTA ANA, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details around its NK cell therapy in neurodegenerative disease, review its preclinical data in Parkinson's disease, and highlight clinical safety and efficacy data from the Company's recently completed Phase 1 clinical trial of SNK01, autologous natural killer cell therapy, in Alzheimer's disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit to be held in Boston, MA, from April 23-25, 2024.
Presentation Details:
Title: Evaluating Adoptive Cellular Immunotherapy for Neurodegeneration with Autologous SNK01
Conference Track: Translational -- Harnessing Cell Therapy & Senescence to Reduce Alzheimer's Pathology in Preclinical Research
Date and Time: Thursday, April 25, 2024, 2:00 pm ET
Dr. Song's presentation will detail how enhanced natural killer cells can maximize the body's ability to destroy diseased and abnormal cells and provide a review of NK cell therapy as an alternative treatment modality to resolve neurodegeneration by harnessing the body's natural immune system, including a discussion on the scientific rationale behind the use of NK cell therapy for the treatment of Parkinson's disease. Dr. Song will also present clinical safety and efficacy data from the Company's recently completed Phase 1 clinical trial evaluating autologous SNK01 NK cell therapy in patients with Alzheimer's disease (NCT04678453).
A copy of the presentation will be available on the Scientific Publications page of the Company's website at https://nkgenbiotech.com/ once the presentation has concluded. Previously disclosed Phase 1 data on the positive effects of SNK01 on amyloid, tau and neuroinflammation biomarkers, which may not be included in this conference presentation, can also be found on the Scientific Publications page.
Recent NKGN News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:01:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:19:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:16:19 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:14:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:11:45 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 06:05:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 11:12:43 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 10:19:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:14:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:02:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:01:25 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/19/2023 06:41:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:39:00 PM
- NKGen Biotech Shares Rise 8% After FDA Clears IND Application for SNK01 • Dow Jones News • 10/24/2023 02:56:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 12:05:14 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM